A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ||||||||||||||||||||||||||
2 | ||||||||||||||||||||||||||
3 | ||||||||||||||||||||||||||
4 | ||||||||||||||||||||||||||
5 | ||||||||||||||||||||||||||
6 | BEYOND BCP FRAMEWORKS | |||||||||||||||||||||||||
7 | ||||||||||||||||||||||||||
8 | * Based on the core values of your organization | |||||||||||||||||||||||||
9 | ||||||||||||||||||||||||||
10 | Business Continuity issues: Immediate term, to be addressed by Inter-disciplinary Operational BCP Task Force. Guidelines: STRESS TEST BCP readiness on two dimensions - Length and Severity of Disruption | |||||||||||||||||||||||||
11 | Strategic issues: Long term, to be addressed by CEO and Senior Leadership. Guidelines - QUESTION, RETHINK and REVISIT all prior decisions/assumptions | |||||||||||||||||||||||||
12 | ||||||||||||||||||||||||||
13 | Employee health, safety and remote working readiness | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
14 | ||||||||||||||||||||||||||
15 | Employee health support systems in case of illness | Contingency planning for CXO illness | ||||||||||||||||||||||||
16 | Expense reimbursement policies | Identification of 'generalists' within the organisation to address challenges that arise | ||||||||||||||||||||||||
17 | Remote working readiness for staff | Evolving organization structure to function in new normal including identification of back-ups to every key role, in case of illness | ||||||||||||||||||||||||
18 | Communication protocols and tools | Key leadership competencies to operate in new normal | ||||||||||||||||||||||||
19 | Technology choices related to employee communication/collaboration | Employee benefits and protections (including insurance) to address pain points and employee engagement | ||||||||||||||||||||||||
20 | Existing human resource deployment | Performance appraisal frameworks | ||||||||||||||||||||||||
21 | Identification of bottlenecks in processes and redesign | Real estate office space requirements | ||||||||||||||||||||||||
22 | Travel restrictions and policies | Key project inventory and prioritize/reprioritize | ||||||||||||||||||||||||
23 | ||||||||||||||||||||||||||
24 | Customer engagement and brand value proposition | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
25 | ||||||||||||||||||||||||||
26 | Customer communication protocols | Short term mission statement - to guide immediate BCP | ||||||||||||||||||||||||
27 | Real time demand estimation | Long term brand positioning and messaging | ||||||||||||||||||||||||
28 | Real time pain points and feedback loops | Definition of who is your customer and what you want your brand to mean to them | ||||||||||||||||||||||||
29 | Customer engagement policies | Review customer segments that may vanish or be fundamentally altered | ||||||||||||||||||||||||
30 | Customer engagement processes/alternative mediums of engagement | Value of current product portfolio in new normal and future product roadmap | ||||||||||||||||||||||||
31 | Helping customers avail scheme/dispensation benefits | Collaboration with partners who have aligned customer interests | ||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||
33 | Financial sustainability | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
34 | ||||||||||||||||||||||||||
35 | Short term cash flow scenarios and evaluation of liquidity | Finance team - resourcing and capabilities | ||||||||||||||||||||||||
36 | BCP budget | Review business economics and evaluate whether they still make sense | ||||||||||||||||||||||||
37 | Budget vs actual tracking in real time | Debt service - renegotiate or delay | ||||||||||||||||||||||||
38 | Assess potential revenue effects | Capital availability assumptions - equity and debt | ||||||||||||||||||||||||
39 | Manage discretionary spending | Investor mindset with respect to your sector | ||||||||||||||||||||||||
40 | Pricing/contract renegotiation | Next fund raise assumptions - timing and quantum | ||||||||||||||||||||||||
41 | Credit risk monitoring | Multiple scenario analyses - based on equity availability | ||||||||||||||||||||||||
42 | Collections acceleration | Areas to overinvest (including acquisitions) | ||||||||||||||||||||||||
43 | Working capital optimization | Areas to pause or stop investing | ||||||||||||||||||||||||
44 | Potential covenant violations and representation & warranties violations | Opportunities to divest/monetize | ||||||||||||||||||||||||
45 | Cross/default (if lender or borrower) | Alternative sources of funds (including creative ways of looking at revenue stream) | ||||||||||||||||||||||||
46 | Monitor for increased fraud | Profitability vs growth focus | ||||||||||||||||||||||||
47 | Ensure there is sufficient insurance and other protection measures | |||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||
49 | Vendor and supply chain BCP | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
50 | ||||||||||||||||||||||||||
51 | Assessment of vendor supply chains (backend and front end | Key vendor dependencies and redundancies | ||||||||||||||||||||||||
52 | Vendor BCP plans | Evaluate alternate vendors if possible | ||||||||||||||||||||||||
53 | Status of vendor contracts and risk to renewal on timing, pricing etc. | Financial distress in key vendors/sectors | ||||||||||||||||||||||||
54 | Monitor vendor/supply chain disruption - process, metrics, responsibility | Build vs buy decisions | ||||||||||||||||||||||||
55 | Re-evaluate target recovery times in case of disruption | |||||||||||||||||||||||||
56 | Country risk assessments | |||||||||||||||||||||||||
57 | Contact databases and escalation protocols | |||||||||||||||||||||||||
58 | Process readiness for remote and paperless processing | |||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||
60 | Technology and data security | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
61 | ||||||||||||||||||||||||||
62 | Ensure all employees have the technology to work remotely | Team and capabilities | ||||||||||||||||||||||||
63 | Availability of tools and capacity planning for: | Financial distress in key vendors/sectors | ||||||||||||||||||||||||
64 | - Customer facing technology | Ongoing tech projects - relevance and importance | ||||||||||||||||||||||||
65 | - Internal technology | Product roadmap and relevance | ||||||||||||||||||||||||
66 | - Vendor facing technology | Build/buy/acquire decisions and opportunities | ||||||||||||||||||||||||
67 | Cloud-based document storage | |||||||||||||||||||||||||
68 | Data protection and backups | |||||||||||||||||||||||||
69 | Cybersecurity and breach protocols (evaluate shorter VAPT cycles) | |||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | Legal, contracts and regulatory | Business Continuity Issues | Strategic Issues | |||||||||||||||||||||||
72 | ||||||||||||||||||||||||||
73 | Reporting requirements for employees testing positive | Contingent legal and contractual risks | ||||||||||||||||||||||||
74 | Force majeure rights under key contracts | Related contracts – will failure to perform one contract have implications for other contracts? | ||||||||||||||||||||||||
75 | Customer grievance monitoring and actions | Long-term regulatory reporting requirements/date changes | ||||||||||||||||||||||||
76 | Material adverse change clauses | Regulatory environment and direction | ||||||||||||||||||||||||
77 | Notification obligations | - Customer protection | ||||||||||||||||||||||||
78 | Damages in case certain services cannot be delivered | - Technology usage | ||||||||||||||||||||||||
79 | Termination rights | - Pricing controls | ||||||||||||||||||||||||
80 | Short-term regulatory reporting requirements/date changes | International policy trends | ||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | Reference Sources: | |||||||||||||||||||||||||
83 | Ernst & Young (Responding to COVID-19_18Mar.pdf) | |||||||||||||||||||||||||
84 | https://www.allenovery.com/en-gb/global/news-and-insights/publications/covid-19-novel-coronavirus-10-key-points-for-effective-contingency-planning | |||||||||||||||||||||||||
85 | https://www.mwe.com/insights/covid-19-contingency-planning-checklist-and-considerations-for-corporates-and-portfolio-companies-of-private-equity-funds-to-manage-the-crisis/ | |||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||
100 |